NCT02144662View on ClinicalTrials.gov

Prognostic Factors for Visual Improvement in Patients Undergoing Intravitreal Ranibizumab for Retinal Vein Occlusion

NACompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

January 31, 2017

Study Completion Date

April 30, 2017

Conditions
Researcher-Subject Relations
Interventions
DRUG

Ranibizumab

0.5mg ranibizumab intravitreal injection

All Listed Sponsors
lead

St. Marianna University School of Medicine

OTHER

NCT02144662 - Prognostic Factors for Visual Improvement in Patients Undergoing Intravitreal Ranibizumab for Retinal Vein Occlusion | Biotech Hunter | Biotech Hunter